Student or educator? Sign up with your school email and get 6 months of Pro free.
CoChat

The DOI matches its Crossref record; 46 of the 46 references it cites were found in a registry or an index.

Genome-Wide Methylation Analyses in Glioblastoma Multiforme

Open access

Abstract

Few studies had investigated genome-wide methylation in glioblastoma multiforme (GBM). Our goals were to study differential methylation across the genome in gene promoters using an array-based method, as well as repetitive elements using surrogate global methylation markers. The discovery sample set for this study consisted of 54 GBM from Columbia University and Case Western Reserve University, and 24 brain controls from the New York Brain Bank. We assembled a validation dataset using methylation data of 162 TCGA GBM and 140 brain controls from dbGAP. HumanMethylation27 Analysis Bead-Chips (Illumina) were used to interrogate 26,486 informative CpG sites in both the discovery and validation datasets. Global methylation levels were assessed by analysis of L1 retrotransposon (LINE1), 5 methyl-deoxycytidine (5m-dC) and 5 hydroxylmethyl-deoxycytidine (5hm-dC) in the discovery dataset. We validated a total of 1548 CpG sites (1307 genes) that were differentially methylated in GBM compared to controls. There were more than twice as many hypomethylated genes as hypermethylated ones. Both the discovery and validation datasets found 5 tumor methylation classes. Pathway analyses showed that the top ten pathways in hypomethylated genes were all related to functions of innate and acquired immunities. Among hypermethylated pathways, transcriptional regulatory network in embryonic stem cells was the most significant. In the study of global methylation markers, 5m-dC level was the best discriminant among methylation classes, whereas in survival analyses, high level of LINE1 methylation was an independent, favorable prognostic factor in the discovery dataset. Based on a pathway approach, hypermethylation in genes that control stem cell differentiation were significant, poor prognostic factors of overall survival in both the discovery and validation datasets. Approaches that targeted these methylated genes may be a future therapeutic goal.

Overview

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.1371/journal.pone.0089376

Cites

46 of 46 references verified0 citation errors · 0 not checkable

Statistics

Figures

Figure 1 Heat map of differential methylation in the discovery dataset. Heat map based on a set of 1864 CpG sites that significantly segregated GBM and control brain tissues into six methylation classes in the discovery dataset. Methylation class numbers are marked inside the annotation bar. The heat map columns represented CpG probes, and the rows are tumor and control brain samples. In the color scale, relative hypermethlyation is denoted by a shift towards the red color, and relative hypomethylation towards blue. Neutral methylation is gray.
Figure 1 Heat map of differential methylation in the discovery dataset. Heat map based on a set of 1864 CpG sites that significantly segregated GBM and control brain tissues into six methylation classes in the discovery dataset. Methylation class numbers are marked inside the annotation bar. The heat map columns represented CpG probes, and the rows are tumor and control brain samples. In the color scale, relative hypermethlyation is denoted by a shift towards the red color, and relative hypomethylation towards blue. Neutral methylation is gray.CC BY · PubMed Central
Figure 2 Histograms of median |Δβ| distributions. a. The histogram showing a range of median |Δβ| of significant CpG sites from the discovery dataset; b. the histogram of a range of median |Δβ| of significant CpG sites from the validation dataset. Red bars denote the number of hypermethylated CpGs, and blue bar represented hypomethylated CpGs.
Figure 2 Histograms of median |Δβ| distributions. a. The histogram showing a range of median |Δβ| of significant CpG sites from the discovery dataset; b. the histogram of a range of median |Δβ| of significant CpG sites from the validation dataset. Red bars denote the number of hypermethylated CpGs, and blue bar represented hypomethylated CpGs.CC BY · PubMed Central
Figure 3 Principal component analyses (PCA) of the discovery and validation datasets. a. In the discovery dataset, the 5 tumor and 1 control methylation classes were represented by the first 3 principal components (PCs) in x, y and z axes in 3 dimensional space. b. In the validation dataset, 5 tumors and 2 control classes were represented by the first 3 PCs in 3 dimensional space.
Figure 3 Principal component analyses (PCA) of the discovery and validation datasets. a. In the discovery dataset, the 5 tumor and 1 control methylation classes were represented by the first 3 principal components (PCs) in x, y and z axes in 3 dimensional space. b. In the validation dataset, 5 tumors and 2 control classes were represented by the first 3 PCs in 3 dimensional space.CC BY · PubMed Central
Figure 4 Heat map of differential methylation in the validation dataset. Heat map based on a set of 2445 CpG sites that significantly segregated GBM and control brain tissues into seven methylation classes in the validation dataset. Annotations were the same as Figure 1.
Figure 4 Heat map of differential methylation in the validation dataset. Heat map based on a set of 2445 CpG sites that significantly segregated GBM and control brain tissues into seven methylation classes in the validation dataset. Annotations were the same as Figure 1.CC BY · PubMed Central
Figure 5 The most significant canonical pathways represented in our validated gene list. a. The horizontal blue bars showed the top10 significant canonical pathways that were altered epigenetically in the hypomethylated gene set, using Ingenuity Pathway Analysis (IPA). The orange square denotes the ratio of number of genes presented in our dataset over the total number of genes in that pathway. The top horizontal axis represents FDR (Benjamin-Hochberg) corrected P value, and the bottom one denotes ratio of number of genes presented in the dataset over the total number of genes. The vertical dotted line (in orange) represents the threshold of statistical significance. b. The 5 significant canonical pathways enriched in the hypermethylated gene set. Annotation is the same as the hypomethylated gene list.
Figure 5 The most significant canonical pathways represented in our validated gene list. a. The horizontal blue bars showed the top10 significant canonical pathways that were altered epigenetically in the hypomethylated gene set, using Ingenuity Pathway Analysis (IPA). The orange square denotes the ratio of number of genes presented in our dataset over the total number of genes in that pathway. The top horizontal axis represents FDR (Benjamin-Hochberg) corrected P value, and the bottom one denotes ratio of number of genes presented in the dataset over the total number of genes. The vertical dotted line (in orange) represents the threshold of statistical significance. b. The 5 significant canonical pathways enriched in the hypermethylated gene set. Annotation is the same as the hypomethylated gene list.CC BY · PubMed Central
Figure 6 Enrichment of PRC2 and H3K27me3 in our validated gene list. Venn diagram showing the frequency of enrichment of PRC2 targets (EZH2, SUZ12, EED) and H3K27me3 in embryonic stem cells from our list of validated genes. The number of methylated genes for each enriched target and their overlaps were represented in corresponding areas inside the ellipses. Please note that overlapping areas are not drawn to scale.
Figure 6 Enrichment of PRC2 and H3K27me3 in our validated gene list. Venn diagram showing the frequency of enrichment of PRC2 targets (EZH2, SUZ12, EED) and H3K27me3 in embryonic stem cells from our list of validated genes. The number of methylated genes for each enriched target and their overlaps were represented in corresponding areas inside the ellipses. Please note that overlapping areas are not drawn to scale.CC BY · PubMed Central
Figure 7 Levels of global methylation markers among methylation classes. a. Levels of 5m-dC between brain controls and tumors, and among methylation classes. Red, yellow and green lines (dotted) denoted pairwise comparison between two classes and the P values of their comparisons. b. Levels of LINE1 between brain controls and tumors, and among methylation classes. c. Levels of 5hm-dC between brain controls and tumors, and among methylation classes.
Figure 7 Levels of global methylation markers among methylation classes. a. Levels of 5m-dC between brain controls and tumors, and among methylation classes. Red, yellow and green lines (dotted) denoted pairwise comparison between two classes and the P values of their comparisons. b. Levels of LINE1 between brain controls and tumors, and among methylation classes. c. Levels of 5hm-dC between brain controls and tumors, and among methylation classes.CC BY · PubMed Central
Figure 8 Adjusted Cox proportional hazard survival curves based on ESC index percentiles. a. Adjusted Cox survival curve of the discovery dataset, illustrating survival of subjects at the 25th, 50th and 75th percentiles of ESC index. b. Adjusted Cox survival curve of the validation dataset, illustrating survival of subjects at the 25th, 50th and 75th percentiles of ESC index.
Figure 8 Adjusted Cox proportional hazard survival curves based on ESC index percentiles. a. Adjusted Cox survival curve of the discovery dataset, illustrating survival of subjects at the 25th, 50th and 75th percentiles of ESC index. b. Adjusted Cox survival curve of the validation dataset, illustrating survival of subjects at the 25th, 50th and 75th percentiles of ESC index.CC BY · PubMed Central

Verification

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Claims other papers make about this one

Each is checked against this paper’s own text: does it say what the citing paper says it does?

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Citations

Cites

Show all 46 references

Cited by

See all 54

Metadata

Authors
Lai, R. K., Chen, Y., Guan, X., Nousome, D., Sharma, C., Canoll, P., Bruce, J., Sloan, A. E., Cortes, E., Vonsattel, J.-P., Su, T., Delgado-Cruzata, L., Gurvich, I., Santella, R. M., Ostrom, Q., Lee, A., Gregersen, P., & Barnholtz-Sloan, J.
Affiliations
  • University of Southern California (US)
  • Case Comprehensive Cancer Center (US)
  • Columbia University (US)
  • University Hospitals Cleveland Medical Center (US)
  • Herbert Irving Comprehensive Cancer Center (US)
  • North Shore University Hospital (US)
Corresponding author
Lai, Rose K.
Venue
PLoS ONE
Published
2014-02-21
Volume
9
Issue
2
Pages
e89376
ISSN
1932-6203 (ISSN-L)
OpenAlex
W2036863866
Cited by
54
References
46
Citations by year
2026: 1 · 2025: 2 · 2024: 1 · 2023: 3 · 2022: 1 · 2021: 9 · 2020: 6 · 2019: 5 · 2018: 5 · 2017: 8 · 2016: 4 · 2015: 9
FWCI
2.87
Type
journal article
Language
en
Open access
Locations
  • PLoS ONE (publishedVersion, cc-by)
  • Europe PMC (PubMed Central) (publishedVersion, cc-by)
  • PubMed Central (publishedVersion, cc-by)
  • PubMed (publishedVersion)
  • CUNY Academic Works (City University of New York) (submittedVersion, cc-by)
  • RePEc: Research Papers in Economics (submittedVersion)
  • DOAJ (DOAJ: Directory of Open Access Journals) (submittedVersion, cc-by-sa)
  • Figshare (submittedVersion, cc-by)
  • Columbia Academic Commons (Columbia University)
Funders
  • National Institutes of Health
  • National Cancer Institute (K07CA127468, R01CA139020, R01CA139020-27064, P30CA043703, P30CA014089)
  • National Institute of Environmental Health Sciences (P30ES009089)
Topics
  • Life Sciences › Biochemistry, Genetics and Molecular Biology › Molecular Biology › Epigenetics and DNA Methylation
  • Health Sciences › Medicine › Oncology › Glioma Diagnosis and Treatment
  • Life Sciences › Biochemistry, Genetics and Molecular Biology › Cancer Research › Cancer-related molecular mechanisms research
Keywords
glioblastoma, DNA methylation, differentially methylated genes, promoter hypermethylation, promoter hypomethylation, LINE-1 retrotransposons, 5-methylcytosine, 5-hydroxymethylcytosine, immune pathways, stem cell differentiation, prognostic factors, overall survival, epigenetic therapy targets
MeSH terms
Adult, Aged, Aged, 80 and over, Brain, Brain Neoplasms, Female, Glioblastoma, Humans, Male, Middle Aged, Promoter Regions, Genetic, CpG Islands, DNA Methylation, Genome-Wide Association Study

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

How to cite

Cite CoChat for the checks on this page, and the paper for its own findings.

This page
CoChat. (2026). Citation check: Genome-Wide Methylation Analyses in Glioblastoma Multiforme. https://app.cochat.ai/papers/10.1371/journal.pone.0089376
The paper
Lai, R. K., Chen, Y., Guan, X., Nousome, D., Sharma, C., Canoll, P., Bruce, J., Sloan, A. E., Cortes, E., Vonsattel, J.-P., Su, T., Delgado-Cruzata, L., Gurvich, I., Santella, R. M., Ostrom, Q., Lee, A., Gregersen, P., & Barnholtz-Sloan, J. (2014). Genome-Wide Methylation Analyses in Glioblastoma Multiforme. PLoS ONE. https://doi.org/10.1371/journal.pone.0089376

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.